Humanized anti-PACAP antibodies and uses thereof

Patent metadata

Field	Value
Publication number	US-10913783-B2
Application number	US-201715487642-A
Country	US
Kind code	B2
Filing date	Apr 14, 2017
Priority date	Apr 15, 2016
Publication date	Feb 9, 2021
Grant date	Feb 9, 2021

Abstract

The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial.

First claim

What is claimed is:

1. A humanized anti-pituitary adenylate cyclase-activating polypeptide (“anti-PACAP”) antibody or antigen binding fragment comprising a heavy chain variable region and a light chain variable region that respectively comprise the amino acid sequences of SEQ ID NOs: 962 and 982; SEQ ID NOs: 1282 and 1302; SEQ ID NOs: 1322 and 1342; SEQ ID NOs: 1362 and 1382; SEQ ID NOs: 1402 and 1422; or SEQ ID NOs: 1442 and 1462.

2. The anti-PACAP antibody or antigen binding fragment of claim 1 , which does not substantially bind to human Vasoactive Intestinal Peptide (“VIP”).

3. The anti-PACAP antibody or antigen binding fragment of claim 1 , which elicits one or more of the following effects: (a) inhibits or neutralizes at least one biological effect elicited by pituitary adenylate cyclase-activating polypeptide (“PACAP”); (b) neutralizes or inhibits PACAP activation of at least one of PAC1 receptor (“PAC1-R”), vasoactive intestinal peptide receptor type 1 (“VPAC1-R”), and/or vasoactive intestinal peptide receptor type 2 (“VPAC2-R”); (c) neutralizes or inhibits PACAP activation of each of PAC1-R, VPAC1-R, and VPAC2-R; (d) neutralizes or inhibits PACAP activation of PAC1-R; (e) inhibits PACAP binding to at least one of PAC1-R, VPAC1-R, and/or VPAC2-R; (f) inhibits PACAP binding to each of PAC1-R, VPAC1-R, and/or VPAC2-R; (g) inhibits PACAP binding to PAC1-R-expressing cells; (h) inhibits PACAP-induced cAMP production; and/or (i) when administered to a subject reduces PACAP-induced vasodilation, photophobia, mast cell degranulation and/or neuronal activation.

4. The anti-PACAP antibody or antigen binding fragment of claim 1 , which is suitable for administration to a human subject.

5. The anti-PACAP antibody or antigen binding fragment according to claim 1 , wherein said antibody or antigen binding fragment comprises an scFv, Fab fragment, Fab′ fragment, or F(ab′) 2 fragment.

6. The anti-PACAP antibody or antigen binding fragment according to claim 1 , wherein said antibody or antigen binding fragment substantially or entirely lacks N-glycosylation and/or O-glycosylation; said antibody or antigen binding fragment has been modified to alter at least one of effector function, half-life, proteolysis, or glycosylation; and/or said antibody or antigen binding fragment comprises an Fc region containing one or more mutations that alters or eliminates N- and/or O-glycosylation.

7. The anti-PACAP antibody or antigen binding fragment according to claim 1 , wherein said antibody or antigen binding fragment comprises a human constant domain.

8. The anti-PACAP antibody or antigen binding fragment according to claim 7 , wherein said human constant domain is an IgG1, IgG2, IgG3, or IgG4 constant domain.

9. The anti-PACAP antibody or antigen binding fragment according to claim 1 , wherein said antibody or antigen binding fragment comprises an Fc region comprising the sequence of any one of SEQ ID NO: 1244, 1245 or 1246.

10. The anti-PACAP antibody or antigen binding fragment according to claim 1 , wherein said antibody or antigen binding fragment (a) binds to human PACAP38 with a binding affinity (K D ) of less than or equal to 5×10 −5 M, 10 −5 M, 5×10 −6 M, 10 −6 M, 5×10 −7 M, 10 −7 M, 5×10 −8 M, 10 −8 M, 5×10 −9 M, 10 −9 M, 5×10 −10 M, 10 −10 M, 5×10 −11 M, 10 −11 M, 5×10 −12 M, 10 −12 M, 5×10 −13 M, or 10 −13 M; (b) binds to human PACAP38 with a binding affinity (K D ) of less than or equal to 5×10 −10 M, 10 −10 M, 5×10 −11 M, 10 −11 M, 5×10 −12 M, 10 −12 M; (c) binds to human PACAP38 with an off-rate (k d ) of less than or equal to 5×10 −4 s −1 , 10 −4 s −1 , 5×10 −5 s −1 , or 10 −5 s −1 ; (d) binds to human PACAP38 with a K D that is less than about 100 nM, 40 nM, 50 pM, 25 pM, or is between about 10 pM and about 100 pM; (e) has stronger affinity for human PACAP38 as compared to VIP and/or does not bind to VIP; (f) is directly or indirectly attached to a detectable label or therapeutic agent; and/or (g) is linked to at least one effector or functional moiety and/or at least one detectable moiety.

11. A composition suitable for therapeutic, prophylactic, or a diagnostic use comprising a therapeutically, prophylactically or diagnostically effective amount of at least one anti-PACAP antibody or antigen binding fragment according to claim 1 .

12. The composition according to claim 11 , wherein said composition:
a.) is suitable for subcutaneous administration, or is suitable for intravenous or intramuscular administration;
b.) is lyophilized, stabilized, and/or formulated for administration by injection; and/or
c.) further comprises a pharmaceutically acceptable diluent, carrier, solubilizer, emulsifier, preservative, or mixture thereof and/or another active agent.

13. An isolated nucleic acid sequence or nucleic acid sequences encoding an anti-PACAP antibody or antigen binding fragment of claim 1 , or a vector or vectors containing said isolated nucleic acid sequence or sequences.

14. An isolated host cell comprising the isolated nucleic acid sequence or sequences or the vector or vectors of claim 13 .

15. The isolated host cell of claim 14 , wherein said host cell is a mammalian, bacterial, fungal, yeast, avian, amphibian, plant or insect cell, or is a Chinese Hamster Ovary (“CHO”) cell.

16. A method of expressing an anti-PACAP antibody or antigen binding fragment comprising culturing the host cell of claim 14 under conditions that provide for expression of said antibody or antigen binding fragment.

17. A humanized anti-pituitary adenylate cyclase-activating polypeptide (“anti-PACAP”) antibody or antigen binding fragment thereof comprising the heavy chain variable region of SEQ ID NO: 1322 and the light chain variable region of SEQ ID NO: 1342.

18. The anti-PACAP antibody or antigen binding fragment according to claim 17 , further comprising an IgG1 constant domain.

19. The anti-PACAP antibody or antigen binding fragment according to claim 17 , wherein said antibody or antigen binding fragment comprises an Fc region comprising the sequence of any one of SEQ ID NO: 1244, 1245 or 1246.

20. A composition suitable for therapeutic, prophylactic, or a diagnostic use comprising a therapeutically, prophylactically or diagnostically effective amount of at least one anti-PACAP antibody or antigen binding fragment according to claim 17 .

21. The composition according to claim 20 , wherein said composition:
a.) is suitable for subcutaneous administration, or is suitable for intravenous or intramuscular administration;
b.) is lyophilized, stabilized, and/or formulated for administration by injection; and/or
c.) further comprises a pharmaceutically acceptable diluent, carrier, solubilizer, emulsifier, preservative, or mixture thereof and/or another active agent.

22. An isolated nucleic acid sequence or nucleic acid sequences encoding an anti-PACAP antibody or antigen binding fragment of claim 17 , or a vector or vectors containing said isolated nucleic acid sequence or sequences.

23. An isolated host cell comprising the isolated nucleic acid sequence or sequences or the vector or vectors of claim 22 .

24. The isolated host cell of claim 23 , wherein said host cell is a mammalian, bacterial, fungal, yeast, avian, amphibian, plant or insect cell, or is a Chinese Hamster Ovary (“CHO”) cell.

25. A method of expressing an anti-PACAP antibody or antigen binding fragment comprising culturing the host cell of claim 24 under conditions that

Assignees

• Alder Biopharmaceuticals Inc
• H Lundbeck As

Inventors

• Loomis Maria-Cristina
• Garcia-Martinez Leon F
• Dutzar Benjamin H
• Allison Daniel S
• Hendrix Katherine Lee
• Ojala Ethan W
• Fan Pei
• Smith Jeffrey T L
• Latham John A
• Karasek Charlie
• Mulligan Jenny
• Scalley-Kim Michelle
• Stewart Erica
• Rubin Vanessa Lisbeth
• Billgren Jens J

Classifications

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• G01N2333/575

  Hormones · CPC title

• G01N33/6854

  Immunoglobulins · CPC title

• C12N15/63

  Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression · CPC title

• C12N15/09

  Recombinant DNA-technology · CPC title